Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group
Elena Fountzilas(St. Luke's Hospital), G. Koumakis(St Savas Hospital), Ioannis Boukovinas, Zacharenia Saridaki(Clinic Asklepio Larissa), Efthalia Lalla(Theageneio General Hospital), Davide Mauri(University Hospital of Ioannina), Adamantia Nikolaidi(Mitera Hospital), Cleopatra Rapti(Hellenic Airforce General Hospital), Ioannis Kontogiorgos(University of Piraeus), Sofia Karageorgopoulou(National and Kapodistrian University of Athens), Anastasios Boutis(Theageneio General Hospital), Eleni Res(Hospital Agioi Anargyroi), Dimitrios Tryfonopoulos(St Savas Hospital), Georgia-Angeliki Koliou(Hellenic Cooperative Oncology Group), Sofia Karteri(General University Hospital of Patras), Gerasimos Aravantinos(Hospital Agioi Anargyroi), George Fountzilas(Hellenic Cooperative Oncology Group), Giannis Mountzios(Henry Dunant Hospital), Flora Zagouri(National and Kapodistrian University of Athens), Amanda Psyrri(National and Kapodistrian University of Athens), Athina Christopoulou(General University Hospital of Patras), Achilleas Nikolakopoulos(University of Patras), Ioannis Binas(Metropolitan Hospital), Anna Koumarianou(University General Hospital Attikon), Vassiliki Rapti(St Savas Hospital), Evangelia Razis(Hygeia Hospital), Dimitrios Bafaloukos(Metropolitan Hospital), Helena Linardou(Metropolitan Hospital), Evangelia Moirogiorgou(Hygeia Hospital), Athanassios Vozikis(University of Piraeus)
Cited by 38
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
|JNCI Journal of the National Cancer Institute|2008|524